<DOC>
	<DOC>NCT01227616</DOC>
	<brief_summary>The objectives of this study are to compare the efficacy and safety of repeat doses of intravenous (IV) ferumoxytol with IV iron sucrose for the treatment of IDA in subjects with hemodialysis-dependent CKD.</brief_summary>
	<brief_title>A Phase IV Trial of Repeated Doses of Ferumoxytol Compared to Iron Sucrose for the Treatment of Iron Deficiency Anemia in Patients With Chronic Kidney Disease on Hemodialysis</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Anemia, Iron-Deficiency</mesh_term>
	<mesh_term>Deficiency Diseases</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Ferric oxide, saccharated</mesh_term>
	<mesh_term>Ferrosoferric Oxide</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>Key Inclusion Criteria include: 1. Males and females â‰¥18 years of age 2. Diagnosis of CKD 3. Subjects on dialysis must have been on dialysis for at least 3 months prior to screening 4. Female subjects of childbearing potential who are sexually active must be on an effective method of birth control for at least 1 month prior to screening and agree to remain on birth control until completion of participation in the study Key Exclusion Criteria include: 1. History of allergy to either oral or IV iron 2. Female subjects who are pregnant or intend to become pregnant, breastfeeding, within 3 months postpartum, or have a positive serum or urine pregnancy test 3. Parenteral iron therapy within 30 days prior to screening or red blood cell (RBC)/whole blood transfusion within 14 days prior to screening or planned during the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Iron deficiency anemia (IDA), Feraheme, ferumoxytol, chronic kidney disease (CKD), hemodialysis, magnetic resonance imaging (MRI)</keyword>
</DOC>